On March 24, 2026, BridgeBio Oncology Therapeutics, Inc. announced the appointment of Peter Lebowitz, M.D., Ph.D., to its Board of Directors. This decision follows an increase in the Board's size to nine members, a move that reflects the company's commitment to enhancing its governance structure. Dr. Lebowitz will serve as a Class I director, with his term set to expire at the company's 2026 annual meeting of stockholders. He will also join the Nominating and Corporate Governance Committee as well as the Compensation Committee, effective immediately.

Dr. Lebowitz's appointment is significant as he is recognized for his extensive experience in the oncology field, which aligns with BridgeBio's focus on developing innovative therapies for patients with genetic diseases. The Board has confirmed that Dr. Lebowitz meets the independence criteria set forth by the Nasdaq Stock Market, ensuring that his contributions will be unbiased and in the best interest of shareholders.

In terms of compensation, Dr. Lebowitz will receive remuneration consistent with the company's non-employee director compensation policy. This includes a one-time nonqualified stock option grant to purchase 63,350 shares of the company's common stock at an exercise price of $8.72 per share, reflecting the closing price on the Nasdaq Global Market on the date of his appointment.

The addition of Dr. Lebowitz is expected to bolster the Board's expertise and oversight capabilities, particularly in the strategic direction of the company as it navigates the complexities of the biotechnology landscape. This strategic move is anticipated to have a positive impact on the company's governance and operational execution, potentially enhancing shareholder value in the long term.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.